Purchase Order HT941024P0239
Award Date
10/1/24
Potential Completion Date
9/30/27
Potential Value
$46K
Federal Agency
Defense Health Agency
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
PSC Category
J065 - Maint/Repair/Rebuild Of Equipment- Medical, Dental, And Veterinary Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92134, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that specializes in blood safety technologies and pathogen reduction systems. The contract, valued at $45,898.00, is for the maintenance and support of INTERCEPT Blood System illuminators, which are essential components of Cerus's proprietary pathogen reduction process for blood products. The contract has an ultimate completion date of September 26, 2027. Cerus...
This is a $199,584.00 firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that specializes in blood safety technologies. The contract is for the supply of INTERCEPT platelet processing sets, which use the company's proprietary INTERCEPT Blood System to inactivate pathogens in blood components. This system plays a crucial role in reducing the risk of transfusion-transmitted infections in blood products used by military and...
The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
This is a firm-fixed price purchase order awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency within the Department of Veterans Affairs, to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The $82,389 contract is for the supply of INTERCEPT Illuminator 60 Hz systems and associated maintenance services. The illuminators are essential components of Cerus Corporation's proprietary INTERCEPT Blood System,...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...
This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
This federal contract award to Cerus Corporation, a biomedical products company, is for the delivery of INTERCEPT Platelet Processing Kits. The award, valued at $232,128.00, was made by the Defense Health Agency (DHA), a component of the Department of Defense. The contract has a period of performance ending on September 30, 2027. Cerus Corporation's INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, plays a crucial role in reducing...